A study published in The Journal of Medical Economies confirmed that Exparel benefited total hip arthroplasty patients.
Researchers conducted a retrospective analysis of the Premier Healthcare Database from January 2011 to April 2017. They examined 12,589 patients.
Patients receiving Exparel decreased their postsurgical inpatient opioid use, decreased their length of stay by 0.7 days, and had a 1.6- to 1.7-fold higher chance of a home discharge than those who didn't receive Exparel. Exparel patients also faced no increased readmission risk.
Exparel reduced hospitalization costs by $561 in Medicare populations but increased costs in commercial populations by $41.